A human Myogenin promoter modified to be highly active in alveolar rhabdomyosarcoma drives an effective suicide gene therapy. (2021)

First Author: Pruller J
Attributed to:  Understanding and Ameliorating Pathogenesis in FSHD funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/s41417-020-00225-0

PubMed Identifier: 32973362

Publication URI: http://europepmc.org/abstract/MED/32973362

Type: Journal Article/Review

Volume: 28

Parent Publication: Cancer gene therapy

Issue: 5

ISSN: 0929-1903